title: Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
abstract: Hepatitis C virus (HCV) is a major cause of chronic liver disease, with more than 170 million infected individuals worldwide. Genotype 4 is the most frequent cause of chronic hepatitis C in the Middle East and sub-Saharan Africa. It has recently spread to southern Europe. The introduction of all-oral, interferon-free regimens that combine direct-acting antivirals (DAAs) has significantly advanced HCV treatment. High efficacy rates, short treatment duration, and favorable adverse event profiles have been demonstrated with multiple regimens, both with and without ribavirin. This review discusses management of patients with HCV genotype 4 chronic hepatitis, in the era of DAAs.
authors.affiliation: Department of Hepatology, Beaujon Hospital, UNITY, INSERM, UMR1149, Team Viral hepatitis, Centre de Recherche sur l'inflammation, Labex INFLAMEX, Université Denis Diderot Paris 7, 100 Bd du Général Leclerc, Clichy, Cedex 92110, France. Electronic address: tarik.asselah@aphp.fr.
authors.forename: Tarik
authors.initials: T
authors.lastname: Asselah
authors.affiliation: Saint Joseph Hospital, Marseilles 13008, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Bourlière
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents
keywords: Access to treatment; Direct-acting antivirals; Egypt; Ledipasvir; Ombitasvir; Paritaprevir; Screening; Sofosbuvir